Goldman Sachs Comments on Mindray Medical (MR) Following Q2 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Mindray Medical International (MR) Tops Q2 EPS by 2c, Updates FY Guidance
August 11, 2014 5:03 PM EDTMindray Medical International (NYSE: MR) reported Q2 EPS of $0.56, $0.02 better than the analyst estimate of $0.54. Revenue for the quarter came in at $334.5 million versus the consensus estimate of $348.3 million.
Business Outlook for Full Year 2014
The company now expects its full year 2014 net revenues to grow at least 10% over its full year 2013... More
